The defining characteristic of atherosclerosis is the accumulation of cholesterol within the artery wall. This process requires the retention of apoB100- or apoB48-lipoproteins in the subendothelial space. The PI and his colleagues present data that support a hypothesis that the one portion of lipoproteins that causes them to be retained in the subendothelial space is within the NH2- terminal region of apoB (NTAB). A series of experiments is proposed to test this hypothesis in vivo and then to more precisely define the portion of apoB that is required for production of an atherogenic particle.
Aim 1 is to determine the biochemical properties of the interaction between apoB100- and apoB48- lipoproteins and matrix proteins. Lipoprotein-matrix molecular interactions will be studied using isolated matrix components and perfused blood vessels. Our objective will be to define the region of apoB that allows lipoprotein-matrix association.
Aim 2 is to block atherosclerosis development in mice by inhibiting apoB binding to arteries. We have overexpressed apoB17 by adenoviral infection and by creating transgenic mice. We show that apoB17 does not alter plasma levels of lipoproteins and is not associated with the atherogenic lipoproteins. Atherosclerosis-prone mouse models will be used to test the hypothesis that by competing for lipoprotein binding to matrix, soluble apoB fragments decrease atherosclerosis.
Aim 3 is to create atherosclerosis in mice using NTAB associated with a lipid-binding region of apoB. We have produced a construct in which a beta-sheet lipid-binding region of apoB (from apoB29-36) is attached to apoB17. We predict that when this protein is expressed in the liver, it will produce small, cholesterol-containing lipoproteins that will cause atherosclerosis. In contrast, similar levels of cholesterol-containing lipoproteins produced with apoAI attached to this same lipid-binding region will not be atherogenic. These experiments will explain why apoB-containing lipoproteins are pathological. Moreover, the experiments are significant for our understanding of atherosclerosis development and may demonstrate molecular methods to alter apoB retention that could be used in treatment and preventative therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL062301-05
Application #
6638525
Study Section
Metabolism Study Section (MET)
Program Officer
Applebaum-Bowden, Deborah
Project Start
1999-05-01
Project End
2005-04-30
Budget Start
2003-05-01
Budget End
2005-04-30
Support Year
5
Fiscal Year
2003
Total Cost
$358,531
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Kwong, K Y; Niang, S; Literat, A et al. (2006) Expression of transforming growth factor beta (TGF-b1) by human preterm lung inflammatory cells. Life Sci 79:2349-56
Loike, J D; Shabtai, D Y; Neuhut, R et al. (2004) Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol 24:2051-6
Chen, Guangping; Wang, Dongyan; Vikramadithyan, Reeba et al. (2004) Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43:4971-7
Vikramadithyan, Reeba K; Kako, Yuko; Chen, Guangping et al. (2004) Atherosclerosis in perlecan heterozygous mice. J Lipid Res 45:1806-12
Kwong, K Y C; Literat, A; Zhu, N L et al. (2004) Expression of transforming growth factor beta (TGF-beta1) in human epithelial alveolar cells: a pro-inflammatory mediator independent pathway. Life Sci 74:2941-57
Khalil, Maged F; Wagner, William D; Goldberg, Ira J (2004) Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol 24:2211-8
Lee, Pierre S W; Chang, Chenbei; Liu, Dong et al. (2003) Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem 278:27853-63
Lutz, E P; Merkel, M; Kako, Y et al. (2001) Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues. J Clin Invest 107:1183-92
Goldberg, I J; Kako, Y; Lutz, E P (2000) Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Curr Opin Lipidol 11:235-41
Hussain, M M; Obunike, J C; Shaheen, A et al. (2000) High affinity binding between lipoprotein lipase and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity, and is modulated by glycosaminoglycans. J Biol Chem 275:29324-30

Showing the most recent 10 out of 11 publications